Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 62.15
0.00 (0.00%)
Feb 2, 2026, 4:00 PM EST
SHE:301075 Revenue
Tibet Duo Rui Pharmaceutical had revenue of 30.43M CNY in the quarter ending September 30, 2025, a decrease of -39.32%. This brings the company's revenue in the last twelve months to 177.11M, down -38.62% year-over-year. In the year 2024, Tibet Duo Rui Pharmaceutical had annual revenue of 240.63M, down -28.02%.
Revenue (ttm)
177.11M
Revenue Growth
-38.62%
P/S Ratio
27.90
Revenue / Employee
356.35K
Employees
497
Market Cap
4.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 240.63M | -93.67M | -28.02% |
| Dec 31, 2023 | 334.30M | -66.75M | -16.64% |
| Jan 1, 2023 | 401.05M | -128.57M | -24.28% |
| Jan 1, 2022 | 529.62M | 39.45M | 8.05% |
| Dec 31, 2020 | 490.16M | 40.74M | 9.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinhe Biotechnology CO., LTD. | 2.75B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.74B |
| Hunan Fangsheng Pharmaceutical | 1.68B |
| Bide Pharmatech | 1.27B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Tibet Weixinkang Medicine | 1.17B |
| Newland Pharmaceutical | 670.43M |